Syndrome des antiphospholipides
Veille bibliographique : Syndrome des antiphospholipides
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Saccone G et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017 Jan 30 | Lire le résumé |
| Cochery-Nouvellon É et al. Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes. The NOH-ANGIO observational cohort study. Haematologica. 2017 Jan 25 | Lire le résumé |
| Abrahams VM et al. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet. 2017 Apr 20 | Lire le résumé |
| Mimi Kim et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid syndrome Ann Rheum Dis published on January 25, 2018 | Lire le résumé |
| Rashidi A, Fisher SI. Clinical Images: Lupus erythematosus cell. Arthritis & Rheumatology. 2018 May 14 Nakamura H, Fujieda Y, Yasuda S, Nakai M, Atsumi T. Remission of Nephrotic Syndrome After Therapy for Chronic Hepatitis C Virus Infection in a Patient With Systemic Lupus Erythematosus. Ann Intern Med. 2018 May 1; Sciascia Sciascia SS, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Annals of the Rheumatic Diseases. 2018 May 18; annrheumdis-2018-213496. | Lire le résumé |
| Pengo V, Denas G, Zoppellaro G, Padayattil Jose S, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018 Jul 12;blood-2018-04-848333. | Lire le résumé |
| Sanchez A, Montaudie H, Bory P, Belgodere X, Passeron T, Lacour JP, et al. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma. JAMA Dermatology [Internet]. 2018 Sep 19 [cited 2018 Oct 23]; | Lire le résumé |
| Duarte-García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The Epidemiology of Antiphospholipid Syndrome. A Population‐Based Study. Arthritis Rheumatol [Internet]. 8 avr 2019 [cité 23 avr 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40901 | Lire le résumé |
| Duarte-García A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The Epidemiology of Antiphospholipid Syndrome. A Population‐Based Study. Arthritis Rheumatol [Internet]. 8 avr 2019 [cité 23 avr 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40901 | Lire le résumé |
| Gris J-C, Mousty È, Bouvier S, Ripart S, Cochery-Nouvellon É, Fabbro-Peray P, et al. Increased incidence of cancer in the follow-up of obstetric antiphospholipid syndrome within the the NOH-APS cohort., Haematologica. 17 mai 2019;haematol.2018.213991 | Lire le résumé |
| Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. avr 2019;18(4):406‑14 | Lire le résumé |
| Jesús G, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome ( APS ) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG Int J Obstet Gynaecol [Internet]. 24 oct 2018 [cité 14 mai 2019]; Disponible sur: https://onlinelibrary.wiley.com/doi/abs/10.1111/1471-0528.15469 | Lire le résumé |
| Yelnik CM, Lambert M, Drumez E, Le Guern V, Bacri J-L, Guerra MM, et al. Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome. Lupus. sept 2018;27(10):1679 86 | Lire le résumé |
| Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med [Internet]. 15 oct 2019 [cité 23 oct 2019]; | Lire le résumé |
| Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Effect of belimumab treatment on antiphospholipid antibodies levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. Ann Rheum Dis. 11 nov 2019;annrheumdis-2019-216367 | Lire le résumé |
| Lockshin MD, Guerra M, Salmon JE. Elective termination of pregnancy in autoimmune rheumatic diseases. Arthritis Rheumatol [Internet]. 12 mars 2020 [cité 26 mars 2020]; | Lire le résumé |
| You Y, Shi C, Zhou Z, Wang F, Sun Y, Teng J, et al. Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China. Ann Rheum Dis. 15 janv 2021;annrheumdis-2020-219303. | Lire le résumé |
| Ruffatti A, Tonello M, Macor P, Calligaro A, Del Ross T, Favaro M, et al. Markers of complement activation in plasma during quiescent phases in catastrophic antiphospholipid syndrome patients. Blood [Internet]. 1 mars 2021 [cité 23 mars 2021]; | Lire le résumé |
| Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. oct 2023;82(10):1258‑70. | Lire le résumé |
| Cimé‐Aké E,Hernández‐Molina G, Llorente‐Chávez A, Martín‐Nares E. Performance of the 2023 American College of Rheumatology/ EULAR Classification Criteria for Antiphospholipid Syndrome in a Mexican Cohort. Arthritis Rheumatol. déc 2024;76(12):1775‐9. | Lire le résumé |
| Ahmadzadeh Y,Magder LS, De Andrade DCO, Paredes‐Ruiz D, Tektonidou MG, Pengo V, et al. Predictors of Mortality in Antiphospholipid Antibody–Positive acr.25503. | Lire le résumé |
| Newman TG,Knight JS. Syndrome des antiphospholipides : une maladie à médiation par anticorps offrant de nouvelles perspectives thérapeutiques. Arthrite rhumatol. 19 mai 2025 ; art.43258 | Lire le résumé |
| Celia AI,Vescovo GM, Sarto G, Alessandri C, Iaconelli A, D’Amario D, et al. Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis. Semin Arthritis Rheum. août 2025;73:152741. | Lire le résumé |
| Undas A,Musiał J, Ząbczyk M. Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances. Rheumatol Int. 29 nov 2025;45(12):279. | Lire le résumé |
| Galarza D,Radin M, Cecchi I, Morotti A, Russo I, Camerlo S, et al. Thrombocytopenia in antiphospholipid syndrome: predictors, prognostic implications, and thrombotic risk in a large cohort study. Thrombosis Research. janv 2026;257:109544. doi:10.1016/j.thromres.2025.109544. | Lire le résumé |
| Herrero López M,Cantera Estefanía R, García Ruiz R, Abando Casuso M, Cruz Barquín H, Flores García J, et al. Development of clinical manifestations in antiphospholipid antibodies carriers according to the 2023 acr/EULAR serological domains. Blood. 3 nov 2025;146(Supplement 1):851‐ 851.doi:10.1182/blood-2025-851 | Lire le résumé |
| Op De Hoek LJ,Camilleri E, Eikenboom JCJ, Klok FA, Le Cessie S, Cannegieter SC, et al. Thrombotic recurrence after anticoagulation cessation in patients with antiphospholipid syndrome and antiphospholipid antibody negativization: a systematic review & meta-analysis. Journal of Thrombosis and Haemostasis mars 2026;S153878362600139X. doi:10.1016/j.jtha.2026.02.021 | Lire le résumé |
| Alijotas-Reig J,Esteve-Valverde E, Sáez-Comet L, Anunciación-Llunell A, Ferrer-Oliveras R, Lefkou E, et al. Impact of the 2023 ACR/EULAR antiphospholipid syndrome criteria in 1200 women with prior obstetric antiphospholipid syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology. mai 2026;321:115055. doi:10.1016/j.ejogrb.2026.115055 | Lire le résumé |